Press Releases

Jun 07, 2023
Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP, total bilirubin, ALT, and GGT at 12 weeks OCA 5-10 mg + bezafibrate 400 mg also showed rapid
Apr 27, 2023
Seven abstracts in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH)   accepted at EASL 2023 Accepted abstracts include podium presentation of new data from the planned interim analysis of a Phase 2 study of investigational combination of obeticholic acid (OCA)   and

Shareholder Tools